You may find more results for this query on our sister sites: GenomeWeb and 360Dx.
The trial will assess vopratelimab and Jounce's PD-1 inhibitor in NSCLC patients, and evaluate the ability of an RNA signature to predict response.
Researchers have identified immune cell gene expression signatures that could one day be developed into tests to predict response to treatment.
In patients with Luminal B tumors the CDK4/6 inhibitor ribociclib along with hormonal therapy produced response rates similar to multi-agent chemotherapy.
Investigators compared expression in different men across the genes from three commercial panels, arguing that the findings highlight important unknowns.
Authors concluded that all three assays — Oncotype DX, EndoPredict, and Prosigna — met Canadian thresholds for cost-effectiveness and urged caution in considering the findings.
The researchers have used nCounter, an FDA-cleared platform from NanoString Technologies, to develop their gene expression assay for subtype classification.
Using samples from different points in patients' treatment, researchers employed a variety of tools, including NanoString's GeoMx DSP, to explore potential response markers.
The new additions reflect data published this summer in the TAILORx trial, which speak to the chemopredictive ability of Genomic Health's Oncotype DX.
Although a draft guidance last month recommended against use of molecular tests to guide chemotherapy, the group's finalized decision is subject to price negotiation and other adjustments.